Advances in pathological diagnosis of mesothelioma: what pulmonologists should know

Amber Louw, Arash Badiei, Jenette Creaney, Ming S. Chai, Y. C.Gary Lee

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Malignant pleural mesothelioma (MPM) is a universally fatal illness with a rising incidence, particularly in developing countries. The diagnosis can be challenging and require repeated investigations with implications for the patient and healthcare system. RECENT FINDINGS: Distinguishing between benign/reactive and malignant mesothelial proliferations can be challenging. Cytological diagnosis of MPM from pleural fluid is as reliable as histological analysis of tissue biopsies in epithelioid MPM - an approach endorsed by the International Academy of Cytology. Identification of BRCA1-associated protein 1 (BAP1) and cyclin-dependent kinase inhibitor 2A (CDKN2A) gene mutations in MPM have led to the development of new ancillary tests that can streamline the diagnostic pathway. The prognostic values of these molecules are being investigated. Clinicians should be aware of the recently described BAP1 tumor predisposition syndrome and offer genetic investigations in potential patients. Routine use of prophylactic radiotherapy in MPM patients after pleural interventions has been disproved in a randomized trial. SUMMARY: Diagnosis of epithelioid MPM can be established on pleural fluid analysis in most patients. The use of BAP1 immunostaining and CDKN2A/p16 fluorescence in-situ hybridization are particularly useful in distinguishing benign from malignant mesothelial proliferations. Clinicians should ensure these investigations are available in the pathological assessment of cases to minimize invasive investigations and the associated risks.

Original languageEnglish
Pages (from-to)354-361
Number of pages8
JournalCurrent Opinion in Pulmonary Medicine
Volume25
Issue number4
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Mesothelioma
BRCA1 Protein
Cyclin-Dependent Kinase Inhibitor p16
Fluorescence In Situ Hybridization
Developing Countries
Cell Biology
Malignant Mesothelioma
Pulmonologists
Radiotherapy
Delivery of Health Care
Biopsy
Mutation
Incidence
Genes
Neoplasms

Cite this

@article{eaed4572699d48a69df68d02258ce4b9,
title = "Advances in pathological diagnosis of mesothelioma: what pulmonologists should know",
abstract = "PURPOSE OF REVIEW: Malignant pleural mesothelioma (MPM) is a universally fatal illness with a rising incidence, particularly in developing countries. The diagnosis can be challenging and require repeated investigations with implications for the patient and healthcare system. RECENT FINDINGS: Distinguishing between benign/reactive and malignant mesothelial proliferations can be challenging. Cytological diagnosis of MPM from pleural fluid is as reliable as histological analysis of tissue biopsies in epithelioid MPM - an approach endorsed by the International Academy of Cytology. Identification of BRCA1-associated protein 1 (BAP1) and cyclin-dependent kinase inhibitor 2A (CDKN2A) gene mutations in MPM have led to the development of new ancillary tests that can streamline the diagnostic pathway. The prognostic values of these molecules are being investigated. Clinicians should be aware of the recently described BAP1 tumor predisposition syndrome and offer genetic investigations in potential patients. Routine use of prophylactic radiotherapy in MPM patients after pleural interventions has been disproved in a randomized trial. SUMMARY: Diagnosis of epithelioid MPM can be established on pleural fluid analysis in most patients. The use of BAP1 immunostaining and CDKN2A/p16 fluorescence in-situ hybridization are particularly useful in distinguishing benign from malignant mesothelial proliferations. Clinicians should ensure these investigations are available in the pathological assessment of cases to minimize invasive investigations and the associated risks.",
author = "Amber Louw and Arash Badiei and Jenette Creaney and Chai, {Ming S.} and Lee, {Y. C.Gary}",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/MCP.0000000000000578",
language = "English",
volume = "25",
pages = "354--361",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1531-6971",
publisher = "Lippincott Williams & Wilkins",
number = "4",

}

Advances in pathological diagnosis of mesothelioma : what pulmonologists should know. / Louw, Amber; Badiei, Arash; Creaney, Jenette; Chai, Ming S.; Lee, Y. C.Gary.

In: Current Opinion in Pulmonary Medicine, Vol. 25, No. 4, 01.07.2019, p. 354-361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advances in pathological diagnosis of mesothelioma

T2 - what pulmonologists should know

AU - Louw, Amber

AU - Badiei, Arash

AU - Creaney, Jenette

AU - Chai, Ming S.

AU - Lee, Y. C.Gary

PY - 2019/7/1

Y1 - 2019/7/1

N2 - PURPOSE OF REVIEW: Malignant pleural mesothelioma (MPM) is a universally fatal illness with a rising incidence, particularly in developing countries. The diagnosis can be challenging and require repeated investigations with implications for the patient and healthcare system. RECENT FINDINGS: Distinguishing between benign/reactive and malignant mesothelial proliferations can be challenging. Cytological diagnosis of MPM from pleural fluid is as reliable as histological analysis of tissue biopsies in epithelioid MPM - an approach endorsed by the International Academy of Cytology. Identification of BRCA1-associated protein 1 (BAP1) and cyclin-dependent kinase inhibitor 2A (CDKN2A) gene mutations in MPM have led to the development of new ancillary tests that can streamline the diagnostic pathway. The prognostic values of these molecules are being investigated. Clinicians should be aware of the recently described BAP1 tumor predisposition syndrome and offer genetic investigations in potential patients. Routine use of prophylactic radiotherapy in MPM patients after pleural interventions has been disproved in a randomized trial. SUMMARY: Diagnosis of epithelioid MPM can be established on pleural fluid analysis in most patients. The use of BAP1 immunostaining and CDKN2A/p16 fluorescence in-situ hybridization are particularly useful in distinguishing benign from malignant mesothelial proliferations. Clinicians should ensure these investigations are available in the pathological assessment of cases to minimize invasive investigations and the associated risks.

AB - PURPOSE OF REVIEW: Malignant pleural mesothelioma (MPM) is a universally fatal illness with a rising incidence, particularly in developing countries. The diagnosis can be challenging and require repeated investigations with implications for the patient and healthcare system. RECENT FINDINGS: Distinguishing between benign/reactive and malignant mesothelial proliferations can be challenging. Cytological diagnosis of MPM from pleural fluid is as reliable as histological analysis of tissue biopsies in epithelioid MPM - an approach endorsed by the International Academy of Cytology. Identification of BRCA1-associated protein 1 (BAP1) and cyclin-dependent kinase inhibitor 2A (CDKN2A) gene mutations in MPM have led to the development of new ancillary tests that can streamline the diagnostic pathway. The prognostic values of these molecules are being investigated. Clinicians should be aware of the recently described BAP1 tumor predisposition syndrome and offer genetic investigations in potential patients. Routine use of prophylactic radiotherapy in MPM patients after pleural interventions has been disproved in a randomized trial. SUMMARY: Diagnosis of epithelioid MPM can be established on pleural fluid analysis in most patients. The use of BAP1 immunostaining and CDKN2A/p16 fluorescence in-situ hybridization are particularly useful in distinguishing benign from malignant mesothelial proliferations. Clinicians should ensure these investigations are available in the pathological assessment of cases to minimize invasive investigations and the associated risks.

UR - http://www.scopus.com/inward/record.url?scp=85067524740&partnerID=8YFLogxK

U2 - 10.1097/MCP.0000000000000578

DO - 10.1097/MCP.0000000000000578

M3 - Article

VL - 25

SP - 354

EP - 361

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1531-6971

IS - 4

ER -